These abstracts and posters will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which will be held Feb. 26-28 at the Moscone West Conference Center, ...
On Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript “Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma” was accepted for ...
Please provide your email address to receive an email when new articles are posted on . KidneyIntelX is a prognostic test that incorporates machine learning and predictive biomarkers. Clinical ...
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TELO:CA) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a study further ...
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...
Myriad Genetics (MYGN) announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an ‘Advanced Tool’ in the fight ...
Telo Genomics Corp (TSE:TELO) has released an update. Telo Genomics Corp has revealed promising results for its TeloViewSMM prognostic test, which outperformed existing models in identifying high and ...
A new study found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. Published in Nature Communications, a new study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results